BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 27659016)

  • 1. Hypoxia-Inducible Factor 2α Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster.
    Fliedner SM; Shankavaram U; Marzouca G; Elkahloun A; Jochmanova I; Daerr R; Linehan WM; Timmers H; Tischler AS; Papaspyrou K; Brieger J; de Krijger R; Breza J; Eisenhofer G; Zhuang Z; Lehnert H; Pacak K
    Neoplasia; 2016 Sep; 18(9):567-76. PubMed ID: 27659016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas.
    Shankavaram U; Fliedner SM; Elkahloun AG; Barb JJ; Munson PJ; Huynh TT; Matro JC; Turkova H; Linehan WM; Timmers HJ; Tischler AS; Powers JF; de Krijger R; Baysal BE; Takacova M; Pastorekova S; Gius D; Lehnert H; Camphausen K; Pacak K
    Neoplasia; 2013 Apr; 15(4):435-47. PubMed ID: 23555188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis.
    Comino-Méndez I; de Cubas AA; Bernal C; Álvarez-Escolá C; Sánchez-Malo C; Ramírez-Tortosa CL; Pedrinaci S; Rapizzi E; Ercolino T; Bernini G; Bacca A; Letón R; Pita G; Alonso MR; Leandro-García LJ; Gómez-Graña A; Inglada-Pérez L; Mancikova V; Rodríguez-Antona C; Mannelli M; Robledo M; Cascón A
    Hum Mol Genet; 2013 Jun; 22(11):2169-76. PubMed ID: 23418310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome.
    Taïeb D; Yang C; Delenne B; Zhuang Z; Barlier A; Sebag F; Pacak K
    J Clin Endocrinol Metab; 2013 May; 98(5):E908-13. PubMed ID: 23539726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonmosaic somatic HIF2A mutations associated with late onset polycythemia-paraganglioma syndrome: Newly recognized subclass of polycythemia-paraganglioma syndrome.
    Pang Y; Gupta G; Jha A; Yue X; Wang H; Huynh TT; Li A; Li L; Baker E; Chew E; Feelders RA; Korpershoek E; Zhuang Z; Yang C; Pacak K
    Cancer; 2019 Apr; 125(8):1258-1266. PubMed ID: 30644531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas.
    López-Jiménez E; Gómez-López G; Leandro-García LJ; Muñoz I; Schiavi F; Montero-Conde C; de Cubas AA; Ramires R; Landa I; Leskelä S; Maliszewska A; Inglada-Pérez L; de la Vega L; Rodríguez-Antona C; Letón R; Bernal C; de Campos JM; Diez-Tascón C; Fraga MF; Boullosa C; Pisano DG; Opocher G; Robledo M; Cascón A
    Mol Endocrinol; 2010 Dec; 24(12):2382-91. PubMed ID: 20980436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIF-2alpha: Achilles' heel of pseudohypoxic subtype paraganglioma and other related conditions.
    Tella SH; Taïeb D; Pacak K
    Eur J Cancer; 2017 Nov; 86():1-4. PubMed ID: 28946040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas.
    Taïeb D; Barlier A; Yang C; Pertuit M; Tchoghandjian A; Rochette C; Zattara-Canoni H; Figarella-Branger D; Zhuang Z; Pacak K; Metellus P
    J Neurooncol; 2016 Feb; 126(3):473-81. PubMed ID: 26514359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polycythemia and paraganglioma with a novel somatic HIF2A mutation in a male.
    Toyoda H; Hirayama J; Sugimoto Y; Uchida K; Ohishi K; Hirayama M; Komada Y
    Pediatrics; 2014 Jun; 133(6):e1787-91. PubMed ID: 24819565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations.
    Pollard PJ; El-Bahrawy M; Poulsom R; Elia G; Killick P; Kelly G; Hunt T; Jeffery R; Seedhar P; Barwell J; Latif F; Gleeson MJ; Hodgson SV; Stamp GW; Tomlinson IP; Maher ER
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4593-8. PubMed ID: 16954163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
    Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
    Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas.
    Toledo RA; Qin Y; Srikantan S; Morales NP; Li Q; Deng Y; Kim SW; Pereira MA; Toledo SP; Su X; Aguiar RC; Dahia PL
    Endocr Relat Cancer; 2013 Jun; 20(3):349-59. PubMed ID: 23533246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developmental role of PHD2 in the pathogenesis of pseudohypoxic pheochromocytoma.
    Eckardt L; Prange-Barczynska M; Hodson EJ; Fielding JW; Cheng X; Lima JDCC; Kurlekar S; Douglas G; Ratcliffe PJ; Bishop T
    Endocr Relat Cancer; 2021 Oct; 28(12):757-772. PubMed ID: 34658364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas.
    Yang C; Sun MG; Matro J; Huynh TT; Rahimpour S; Prchal JT; Lechan R; Lonser R; Pacak K; Zhuang Z
    Blood; 2013 Mar; 121(13):2563-6. PubMed ID: 23361906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SDHC Promoter Methylation, a Novel Pathogenic Mechanism in Parasympathetic Paragangliomas.
    Bernardo-Castiñeira C; Valdés N; Sierra MI; Sáenz-de-Santa-María I; Bayón GF; Perez RF; Fernández AF; Fraga MF; Astudillo A; Menéndez R; Fernández B; Del Olmo M; Suarez C; Chiara MD
    J Clin Endocrinol Metab; 2018 Jan; 103(1):295-305. PubMed ID: 29126304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a signaling axis HIF-1α/microRNA-210/ISCU independent of SDH mutation that defines a subgroup of head and neck paragangliomas.
    Merlo A; de Quiros SB; Secades P; Zambrano I; Balbín M; Astudillo A; Scola B; Arístegui M; Suarez C; Chiara MD
    J Clin Endocrinol Metab; 2012 Nov; 97(11):E2194-200. PubMed ID: 22977270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of somatic VHL gene mutations in sporadic head and neck paragangliomas in association with activation of the HIF-1α/miR-210 signaling pathway.
    Merlo A; de Quirós SB; de Santa-María IS; Pitiot AS; Balbín M; Astudillo A; Scola B; Arístegui M; Quer M; Suarez C; Chiara MD
    J Clin Endocrinol Metab; 2013 Oct; 98(10):E1661-6. PubMed ID: 23902947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new twist in neuroendocrine tumor research: Pacak-Zhuang syndrome, HIF-2α as the major player in its pathogenesis and future therapeutic options.
    Jochmanova I; Lazurova I
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Jun; 158(2):175-80. PubMed ID: 24781045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of the natural antisense hypoxia-inducible factor-1alpha transcript is associated with malignant pheochromocytoma/paraganglioma.
    Span PN; Rao JU; Oude Ophuis SB; Lenders JW; Sweep FC; Wesseling P; Kusters B; van Nederveen FH; de Krijger RR; Hermus AR; Timmers HJ
    Endocr Relat Cancer; 2011 Jun; 18(3):323-31. PubMed ID: 21422080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome.
    Buffet A; Smati S; Mansuy L; Ménara M; Lebras M; Heymann MF; Simian C; Favier J; Murat A; Cariou B; Gimenez-Roqueplo AP
    J Clin Endocrinol Metab; 2014 Feb; 99(2):E369-73. PubMed ID: 24276449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.